Skip to main content

Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results

Bosiers et al. 20061

Dendermonde, Bonheiden, and Genk, Belgium

Primary patency of GORE® PROPATEN® Vascular Graft

N=55
1 year 84%

Patient characteristics*

Characteristic N %
Rutherford classification*  
3 58 58%
4 16 16%
5 26 26%
Runoff vessels*  
0 7 7
1 51 51%
2 21 21%
3 21 21%
Hypertension** 62 72%
Diabetes** 24 28%
Renal insufficiency** 8 9%

Study details

  • All grafts were thin-wall, ringed, 6 mm diameter configurations
  • Angiography performed immediately after graft implantation to detect technical failures
  • Postoperatively, patients received clopidogrel (75 mg / day) for the first month after surgery, low-molecular-weight heparin (0.6 mL / day) for the first three weeks, and aspirin (100 mg / day) we indefinitely
  • 96% secondary patency at one-year for above-knee fem-pop bypass

In the light of these in vivo results, we speculate that a decrease in platelet and thrombus deposition on the CBAS ePTFE graft surface may have contributed to the promising 1-year patency rates in our clinical series. Although amelioration of intimal hyperplasia is not the primary target of heparinization technology, it is intriguing to consider the possibility that the CBAS graft surface might simultaneously address two sources of graft failure: thrombosis and intimal hyperplasia. — M. Bosiers

Our findings… indicate that use of this graft is an excellent option for infrainguinal bypass grafting in patients with peripheral vascular disease when autologous vein is not available. — M. Bosiers

*N = 100 limbs

**N = 86 patients

1. Bosiers M, Deloose K, Verbist J, et al. Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results. Journal of Vascular Surgery 2006;43(2):313-319.